Actavis PLC (NYSE:ACT)

270.47
Data as of Nov 26
 +0.16 / +0.06%
Today’s Change
156.40
Today|||52-Week Range
272.75
+60.99%
Year-to-Date
Five Prime Therapeutics Up on Deal with Bristol-Myers - Analyst Blog
Nov 26 / Zacks.com
Celldex Therapeutics Surges on Positive Rindopepimut Data - Analyst Blog
Nov 18 / Zacks.com
New Lifetime High Reached: Actavis (ACT)
Nov 26 / TheStreet.com
Actavis Strikes $66 Billion Deal for Botox Maker Allergan - Analyst Blog
Nov 18 / Zacks.com
Why Actavis (ACT) Could Be an Impressive Growth Stock - Tale of the Tape
Nov 26 / Zacks.com
Pharma ETFs in Focus on Allergan Takeover Deal - ETF News And Commentary
Nov 18 / Zacks.com
Endo to Acquire Rights to Testosterone Nasal Gel Natesto - Analyst Blog
Nov 25 / Zacks.com
Stock Market News for November 18, 2014 - Market News
Nov 18 / Zacks.com
Today's Stocks Driving Success For The Drugs Industry
Nov 25 / TheStreet.com
Will Pfizer's Dividend Be Safe?
Nov 18 / MotleyFool.com
Should Allergan Investors Stick With Actavis?
Nov 25 / MotleyFool.com
Actavis' dealmaking builds drug powerhouse
Nov 18 / FT.com
Celgene's PDE4 Inhibitor Otezla Gets Positive CHMP Opinion - Analyst Blog
Nov 24 / Zacks.com
Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Nov 17 / Zacks.com
Supernus Files Trokendi XR Patent Infringement Lawsuit - Analyst Blog
Nov 24 / Zacks.com
Actavis/Allergan: spoiler alert
Nov 17 / FT.com
George Soros Just Bought These 3 Stocks: Should You?
Nov 23 / MotleyFool.com
Tyson jumps after record sales
Nov 17 / FT.com
PPG Is Spot-On; The Hazards of Skepticism: Jim Cramer's Best Blogs
Nov 22 / TheStreet.com
Allergan-Actavis deal follows battle for soul of pharma
Nov 17 / FT.com
#PreMarket Primer: Friday, November 21: Immigration Reform Could Have Lasting Impact ...
Nov 21 / Benzinga
Dag Skattum to rejoin JPMorgan in Europe
Nov 17 / FT.com
Allergan deal sits well on Actavis chief's 'Monopoly board'
Nov 21 / FT.com
Botox maker bought for $66 billion in biggest deal of 2014
Nov 17 / CNNMoney.com
November 21 Premarket Briefing: 10 Things You Should Know
Nov 21 / TheStreet.com
Actavis Rumored to be Close to Acquiring Allergan - Analyst Blog
Nov 17 / Zacks.com
Synergy Pharmaceuticals Drug Fares Well in Phase II Study - Analyst Blog
Nov 20 / Zacks.com
Why Actavis (ACT) Stock Might be a Great Pick - Tale of the Tape
Nov 17 / Zacks.com
The Crucial Thing You're Missing About Many Dividend Stocks
Nov 20 / MotleyFool.com
Stocks: Six things to know before the open
Nov 17 / CNNMoney.com
Celgene Up on Encouraging Long-Term Phase III Otezla Data - Analyst Blog
Nov 19 / Zacks.com
Mallinckrodt Shares Down on Setback for Generic Concerta - Analyst Blog
Nov 14 / Zacks.com
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Nov 19 / Zacks.com
Pharma wars: Upset stomach
Nov 07 / FT.com
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Nov 19 / Zacks.com
Perrigo joins wave of OTC drug deals
Nov 06 / FT.com
Stock Market News for November 19, 2014 - Market News
Nov 19 / Zacks.com
Bill Ackman wins Allergan insider trading lawsuit
Nov 04 / FT.com

To view my watchlist

Not a member yet?

Sign up now for a free account

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2014 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2014. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2014 and/or its affiliates.